Clinical Trials Browser

INDUSTRY × Interventional × Meningeal Carcinomatosis × Clear all

Meningeal Carcinomatosis

NCT07098806 2025-08-01

CA2024-LM-001

Meningeal Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Nervous System Diseases, Nervous System Neoplasms, Pathologic Processes, Central Nervous System Neoplasms, Meningeal Carcinomatosis

NCT00527410 2025-05-30

LMD

Phase 1 Terminated

9 enrolled

CNS

Meningeal Carcinomatosis

NCT05034497 2025-03-26

ReSPECT-LM

Phase 1 Active not recruiting

18 enrolled

CNS

Meningeal Carcinomatosis

NCT05146219 2024-12-30

Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation

Phase 2 Completed

29 enrolled

CNS

Brain Neoplasms, Meningeal Carcinomatosis

NCT03275402 2024-02-13

131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases

Phase 2/3 Terminated

52 enrolled 11 charts

CNS

Neuroblastoma, Meningeal Carcinomatosis

NCT00089245 2023-12-26

Radiolabeled MAB Therapy in Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer

Phase 1 Terminated

177 enrolled

CNSSarcoma

Brain Neoplasms, Medulloblastoma, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor, Meningeal Carcinomatosis, Desmoplastic Small Round Cell Tumor

NCT03613181 2023-04-24

ANGLeD

Phase 3 Unknown

150 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms, Meningeal Neoplasms, Meningeal Carcinomatosis

NCT04315246 2022-07-15

177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma)

Phase 1/2 Withdrawn

CNS

Meningeal Carcinomatosis

NCT02616393 2022-03-16

Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases

Phase 2 Completed

36 enrolled 22 charts

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT02228369 2021-01-05

BLOOM

Phase 1 Completed

108 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT00854867 2014-02-24

Study to Demonstrate the Safety of WBR Administered at the Same Time as Intrathecal Liposomal Cytarabine (DepoCyte®) Versus Intrathecal Liposomal Cytarabine (DepoCyte®) Administered After WBR for the Treatment of Solid Tumour Neoplastic Meningitis in Patients With or Without Brain Metastasis.

Phase 1 Completed

18 enrolled

CNS

Brain Neoplasms, Meningeal Carcinomatosis

Clinical Trials

Zorifertinib With Osimertinib for NSCLC With Meningeal Progression

CA2024-LM-001

LMD

ReSPECT-LM

Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation

131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases

Radiolabeled MAB Therapy in Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer

ANGLeD

177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma)

Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases

BLOOM

Study to Demonstrate the Safety of WBR Administered at the Same Time as Intrathecal Liposomal Cytarabine (DepoCyte®) Versus Intrathecal Liposomal Cytarabine (DepoCyte®) Administered After WBR for the Treatment of Solid Tumour Neoplastic Meningitis in Patients With or Without Brain Metastasis.